Salarius Pharmaceuticals, Inc. (SLRX) Stock Analysis

Salarius Pharmaceuticals, Inc. (SLRX) Healthcare & Pipeline Overview

Salarius Pharmaceuticals, Inc. is a clinical-stage biotechnology firm specializing in epigenetic-based cancer therapies, with Seclidemstat (SP-2577) as its lead candidate targeting advanced solid tumors and Ewing sarcoma. The company distinguishes itself through strategic partnerships and a focus on innovative protein degradation technologies.

What Is the Investment Thesis for SLRX?

Salarius Pharmaceuticals presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's valuation is closely tied to the clinical progress of Seclidemstat (SP-2577), currently in Phase I/II trials. Positive clinical trial results could serve as a significant catalyst, driving substantial stock appreciation. The strategic partnerships with The University of Utah Research Foundation, HLB Life Sciences, and CPRIT provide external validation and resources. The company's small size and limited cash reserves necessitate careful monitoring of its burn rate and potential future capital raises. The P/E ratio is currently -0.78. Investment in Salarius Pharmaceuticals is suitable for investors with a high-risk tolerance and a long-term investment horizon, understanding the inherent uncertainties in clinical-stage drug development.

Based on FMP financials and quantitative analysis

SLRX Key Highlights

Salarius Pharmaceuticals is a clinical-stage biotechnology company focused on epigenetic-based cancer treatments.

• The lead drug candidate, Seclidemstat (SP-2577), is in Phase I/II clinical trials for advanced solid tumors and Ewing sarcoma.
• Strategic partnerships with The University of Utah Research Foundation, HLB Life Sciences, and CPRIT support research and development.
• The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors.
• The company has a market capitalization of $4.92M and a P/E ratio of -0.78.

Who Are SLRX's Competitors?

SLRX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SLRX's Key Strengths?

Proprietary epigenetic-based cancer treatment technologies.

• Lead drug candidate in Phase I/II clinical trials.
• Strategic partnerships with research institutions and pharmaceutical companies.
• Focus on cancers with limited treatment options.

What Are SLRX's Weaknesses?

Limited financial resources.

• Small team of employees.
• High reliance on clinical trial outcomes.
• Dependence on strategic partnerships for funding and expertise.

What Could Drive SLRX Stock Higher?

SLRX catalyst: Data readout from Phase I/II clinical trial of Seclidemstat (SP-2577) for advanced solid tumors and Ewing sarcoma.

• Announcement of new strategic partnerships or licensing agreements.
• Initiation of clinical trials for SP-3164.
• Continued enrollment of patients in clinical trials.

What Are the Key Risks for SLRX?

Financial-distress signal — its Altman Z-Score of -15.54 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Failure of Seclidemstat (SP-2577) in clinical trials.
• Difficulty in securing funding for research and development.
• Competition from larger pharmaceutical companies with more resources.
• Regulatory hurdles and delays in obtaining regulatory approvals.

What Are the Growth Opportunities for SLRX?

• Expansion into New Therapeutic Areas: Salarius Pharmaceuticals has the opportunity to expand the application of Seclidemstat (SP-2577) to other cancer types beyond advanced solid tumors and Ewing sarcoma. This could involve conducting preclinical and clinical studies to evaluate its efficacy in other hematological malignancies or solid tumors. This expansion could significantly broaden the potential market for Seclidemstat, driving revenue growth for Salarius.
• Strategic Partnerships and Licensing Agreements: Salarius Pharmaceuticals can pursue additional strategic partnerships and licensing agreements to accelerate the development and commercialization of its drug candidates. Collaborating with larger pharmaceutical companies or specialized biotech firms can provide access to additional resources, expertise, and market access. Licensing agreements, such as the one with HLB Life Sciences, can generate upfront payments, milestone payments, and royalties, providing non-dilutive funding for research and development. Successful partnerships can enhance the credibility and visibility of Salarius in the biotechnology industry.
• Advancement of SP-3164 Program: The development of SP-3164, a small molecule protein degrader, represents another growth opportunity for Salarius Pharmaceuticals. Protein degradation is an emerging therapeutic modality with the potential to target previously undruggable proteins. Advancing SP-3164 through preclinical and clinical studies could lead to the development of novel therapies for hematological and solid tumors. The market for protein degrader drugs is expected to grow rapidly in the coming years, driven by the increasing demand for targeted cancer therapies.
• Orphan Drug Designation and Regulatory Approvals: Obtaining orphan drug designation for Seclidemstat in specific cancer indications can provide Salarius Pharmaceuticals with regulatory exclusivity, tax credits, and other incentives. Orphan drug designation is granted to drugs that treat rare diseases or conditions affecting fewer than 200,000 people in the United States. Securing regulatory approvals from the FDA and other regulatory agencies is critical for commercializing Seclidemstat and generating revenue. Successful regulatory approvals can significantly increase the value of Salarius Pharmaceuticals.
• Expansion into International Markets: Salarius Pharmaceuticals can expand its geographic reach by commercializing Seclidemstat in international markets. The partnership with HLB Life Sciences provides a foothold in South Korea, but there are opportunities to expand into other Asian countries, Europe, and Latin America. International expansion requires navigating different regulatory landscapes, establishing distribution networks, and adapting marketing strategies to local markets. Successful international expansion can significantly increase the revenue potential for Seclidemstat.

What Are SLRX's Competitive Advantages?

• Proprietary epigenetic-based cancer treatment technologies.
• Strategic partnerships with leading research institutions and pharmaceutical companies.
• Orphan drug designation for Seclidemstat in specific cancer indications (if obtained).

What Does SLRX Do?

Salarius Pharmaceuticals, Inc., established to combat cancer through epigenetic-based treatments, is a clinical-stage biotechnology company headquartered in Houston, Texas. The company's primary focus is on developing innovative therapies for cancers with limited treatment options. Their lead drug candidate, Seclidemstat (SP-2577), a small molecule inhibitor, is currently undergoing Phase I/II clinical trials for the treatment of advanced solid tumors and Ewing sarcoma, a rare bone cancer primarily affecting children and adolescents. In addition to Seclidemstat, Salarius is developing SP-3164, a small molecule protein degrader targeting hematological and solid tumors. Salarius Pharmaceuticals has established strategic partnerships to advance its research and development efforts. These collaborations include an exclusive license agreement with The University of Utah Research Foundation for patent rights related to SP-2577 and related compounds. Furthermore, the company partners with HLB Life Sciences to develop, produce, manufacture, use, and sell Seclidemstat in South Korea. Salarius also collaborates with the Cancer Prevention and Research Institute of Texas (CPRIT) for product development activities and maintains a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. With a small team of two employees, Salarius focuses on efficient drug development and strategic partnerships to maximize its impact in the oncology space.

What Products and Services Does SLRX Offer?

• Develop epigenetic-based cancer treatments.
• Focus on therapies for cancers with limited treatment options.
• Advance Seclidemstat (SP-2577) through clinical trials.
• Develop SP-3164, a small molecule protein degrader.
• Establish strategic partnerships for research and development.
• Identify new indications and biomarkers for SP-2577.

How Does SLRX Make Money?

• Develop and commercialize epigenetic-based cancer therapies.
• Out-license drug candidates to partners for commercialization in specific territories.
• Generate revenue through upfront payments, milestone payments, and royalties from licensing agreements.

What Industry Does SLRX Operate In?

The biotechnology industry is characterized by high-risk, high-reward ventures focused on developing innovative therapies for unmet medical needs. Epigenetic-based cancer treatments represent a growing area of interest, with the potential to address cancers that are resistant to traditional therapies. The competitive landscape includes both large pharmaceutical companies and smaller biotech firms, all vying for market share in specific cancer indications. Salarius Pharmaceuticals operates in this competitive environment, focusing on niche cancer markets with its lead candidate, Seclidemstat. The success of companies like Salarius hinges on positive clinical trial outcomes, strategic partnerships, and effective commercialization strategies.

Who Are SLRX's Key Customers?

• Patients with advanced solid tumors and Ewing sarcoma.
• Hospitals and oncology clinics.
• Pharmaceutical companies and biotech firms through licensing agreements.

The most recent 2 insider filings for Salarius Pharmaceuticals, Inc. break down as 0 sales and 2 purchases. On net that is roughly 8K shares acquired (about $9K) — insiders putting money in tends to read as conviction.

SLRX Valuation & Market Position

With a $4.92M market cap, Salarius Pharmaceuticals, Inc. sits in the micro-cap segment of the market.

Salarius Pharmaceuticals, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -15.54 places it in the distress zone, a signal of elevated financial risk.

Wall Street analysts project Salarius Pharmaceuticals, Inc. revenue of about $11.9M for fiscal 2026, with EPS near $-243.60.

Company Profile

Salarius Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Houston, US. The company is led by CEO Frederick E. Pierce. SLRX has traded publicly since 2015.

SLRX Financials

SLRX Latest News

No recent news available for SLRX.

Salarius Pharmaceuticals, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources